Cmax

Jump to: navigation, search

WikiDoc Resources for Cmax

Articles

Most recent articles on Cmax

Most cited articles on Cmax

Review articles on Cmax

Articles on Cmax in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cmax

Images of Cmax

Photos of Cmax

Podcasts & MP3s on Cmax

Videos on Cmax

Evidence Based Medicine

Cochrane Collaboration on Cmax

Bandolier on Cmax

TRIP on Cmax

Clinical Trials

Ongoing Trials on Cmax at Clinical Trials.gov

Trial results on Cmax

Clinical Trials on Cmax at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cmax

NICE Guidance on Cmax

NHS PRODIGY Guidance

FDA on Cmax

CDC on Cmax

Books

Books on Cmax

News

Cmax in the news

Be alerted to news on Cmax

News trends on Cmax

Commentary

Blogs on Cmax

Definitions

Definitions of Cmax

Patient Resources / Community

Patient resources on Cmax

Discussion groups on Cmax

Patient Handouts on Cmax

Directions to Hospitals Treating Cmax

Risk calculators and risk factors for Cmax

Healthcare Provider Resources

Symptoms of Cmax

Causes & Risk Factors for Cmax

Diagnostic studies for Cmax

Treatment of Cmax

Continuing Medical Education (CME)

CME Programs on Cmax

International

Cmax en Espanol

Cmax en Francais

Business

Cmax in the Marketplace

Patents on Cmax

Experimental / Informatics

List of terms related to Cmax

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Overview

Cmax is a term used in pharmacokinetics refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose. Cmax is the opposite of Cmin, which is the minimum (or trough) concentration that a drug achieves after dosing.[1]

Tmax is the term used in pharmacokinetics to describe the time at which the Cmax is observed.[2]

After an intravenous administration, Cmax and Tmax are closely dependent on the experimental protocol, since the concentrations are always decreasing after the dose. But after oral administration,Cmax and Tmax are dependent on the extent, and the rate of drug absorption and the disposition profile of the drug. They could be used to characterize the properties of different formulations in the same subject.[3]

Short term drug side effects are most likely to occur at or near the Cmax whereas the therapeutic effect of drug with sustained duration of action usually occurs at concentrations slightly above the Cmin.

The Cmax is often measured in an effort to show bioequivalence between a generic and innovator drug product.[4] According to FDA, drug quality BA (bioavailability) and BE (bioequivalence) rely on pharmacokinetic measures such as AUC and Cmax that are reflective of systemic exposure.[5]

See also

Area under the curve (pharmacokinetics)

References

  1. Tracy TS (2004). "Pharmacokinetics". In Stitzel RE, Craig CF. Modern pharmacology with clinical applications. Hagerstwon, MD: Lippincott Williams & Wilkins. p. 49. ISBN 0-7817-3762-1.
  2. http://www.lexjansen.com/phuse/2006/st/st03.pdf
  3. Urso R, Blardi P, Giorgi G (March 2002). "A short introduction to pharmacokinetics". Eur Rev Med Pharmacol Sci. 6 (2–3): 33–44. PMID 12708608.
  4. Midha KK, Rawson MJ, Hubbard JW (October 2005). "The bioequivalence of highly variable drugs and drug products". Int J Clin Pharmacol Ther. 43 (10): 485–98. doi:10.5414/cpp43485. PMID 16240706.
  5. "Bioavailability and Bioequivalence Studies for Orally Administered Drug Products — General Considerations" (PDF). FDA. Retrieved 13 December 2013.

Linked-in.jpg